While BRAF alterations are predominant mechanisms of resistance to EGFR therapy [9,10], we recently identified that ARAF amplification causes resistance to EGFR inhibitors in EGFR mutant lung cancer [11]. This evidence concerns the gene EGFR and lung carcinoma.